Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Cancer Research

Background:

• Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are protein tyrosine kinases implicated in various cancers.
• Co-expression of EGFR and HER2 occurs in ovarian, breast, colon, and prostate cancer subtypes, making them key therapeutic targets.

Purpose of the Study:

• To synthesize and characterize novel TAK-285 derivatives as dual inhibitors of EGFR and HER2.
• To evaluate the biological activity and antiproliferative effects of these derivatives, particularly against prostate carcinoma.

Main Methods:

• Synthesis and characterization of new TAK-285 derivatives (compounds 9a-h).
• In vitro biological evaluation as dual EGFR/HER2 inhibitors, including IC50 determination.
• Selectivity profiling against a kinase panel.
• In vitro antiproliferative assays against prostate carcinoma cell lines (PC3 and 22RV1).
• Mechanistic studies including cell cycle analysis, apoptosis induction, molecular docking, dynamics, and MM-GBSA.

Main Results:

• Compound 9f exhibited potent inhibition against EGFR (IC50 = 2.3 nM) and HER2 (IC50 = 234 nM), showing significant selectivity over staurosporine and TAK-285.
• Compounds 9a-h displayed IC50 values in the low nanomolar range against PC3 and 22RV1 prostate carcinoma cell lines.
• Mechanistic studies supported compound 9f's role as a potent EGFR/HER2 dual inhibitor with effective antiproliferative action.

Conclusions:

• Novel TAK-285 derivatives were successfully synthesized and demonstrated potent dual inhibition of EGFR and HER2.
• Compound 9f shows promising potential as an antiproliferative agent against prostate carcinoma.
• Further investigation into these compounds could lead to new therapeutic strategies for EGFR/HER2-driven cancers.